Amazon to Expand Drone Delivery to 500 U.S. Locations 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Tesla Raises Cybertruck Prices by $5,000 in US 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Nvidia Options Price in $280 Billion Earnings Swing 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., May 01, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report first quarter 2018 financial results on Wednesday, May 9, 2018, after the NASDAQ market close.
The company will not be conducting a conference call in connection with this financial results press release.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic, BMS-986249, a CTLA-4-targeting Probody therapeutic, CX-188, a PD-1-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Investors:
Christopher Keenan
[email protected]
650-383-0823
Media:
Spectrum
Christine Quern
[email protected]
202-587-2588
